Sticky natto fermented soybeans in ceramic bowl

3.45 mmHg Systolic Drop: Nattokinase for Health Conscious Adults

Nattokinase can modestly lower blood pressure and boost the body’s clot-dissolving activity in short-term trials, but the effect is dose-dependent and the evidence base is still thin. Meta-analysis data show modest systolic and diastolic reductions, and mechanism studies confirm real fibrinolytic action. The catch: sample sizes are small, and anyone on blood thinners needs a doctor’s input before starting.

TL;DR:

  • Most consumer nattokinase supplements contain around 2,000 FU per day, with higher doses (6,000 to 10,800 FU) potentially offering more cardiovascular benefits.
  • Its blood clot-dissolving activity persists in plasma for about 8 to 12 hours after ingestion, favoring split doses throughout the day for sustained effect.
  • Combining nattokinase with blood thinners or anticoagulants increases bleeding risk, requiring medical guidance and regular monitoring.
  • Larger, standardized, long-term human trials are needed to confirm its benefits beyond mechanistic and animal-model support.

Table of Contents

What Is Nattokinase and How Does It Work?

Nattokinase is a fibrinolytic enzyme produced when Bacillus subtilis ferments soybeans into natto, the sticky, pungent staple eaten across Japan. Researchers first isolated it in the 1980s after noticing that natto seemed to dissolve blood clots faster than other fermented soy foods in lab tests. That single observation launched decades of research into how a food enzyme might support cardiovascular health.

The enzyme is a serine protease, which means it breaks down proteins at specific points in their structure. What makes nattokinase unusual is that it survives digestion well enough to show measurable activity in the bloodstream after oral ingestion, something most proteases cannot do. A review of nattokinase’s oral antithrombotic activity found detectable fibrinolytic activity in plasma for roughly 8 to 12 hours after a dose, which is one reason some formulations recommend splitting doses across the day to keep circulating activity more consistent.

Several mechanisms appear to drive its cardiovascular effects:

  • Direct fibrin degradation. Nattokinase breaks down fibrin, the protein mesh that forms the structural backbone of blood clots, in a way that mimics the body’s own plasmin enzyme.
  • PAI-1 inactivation. It appears to inhibit plasminogen activator inhibitor-1, a protein that normally slows the body’s natural clot-breakdown process. Suppressing PAI-1 lets the body’s own fibrinolytic system work more efficiently.
  • ACE-related metabolite activity. Some research points to interactions with angiotensin-converting enzyme pathways, which regulate blood vessel constriction and may partly explain the blood pressure effects seen in trials.
  • Anti-inflammatory signaling. Preclinical work has linked nattokinase to suppressed TLR4 (toll-like receptor 4) signaling and reduced reactive oxygen species production, both of which are tied to vascular inflammation.

Nattokinase’s core statistic: plasma activity persists for about 8 to 12 hours after oral intake, based on the same oral antithrombotic review. That absorption window matters because it explains why a single morning dose may not sustain fibrinolytic activity through the evening. It also explains why researchers testing higher-dose protocols often split administration into two servings rather than one.

None of these mechanisms operate in isolation. A supplement that lowers PAI-1 activity while also reducing vascular inflammation is doing something more layered than a simple blood thinner, which is part of why nattokinase gets grouped with bromelain and other proteolytic enzymes as a “functional food” ingredient rather than a drug. The distinction matters for how you should think about dosing and safety, which the sections ahead cover in detail.

Does Nattokinase Lower Blood Pressure? What the Meta-Analyses Show

The strongest clinical signal for nattokinase right now involves blood pressure, and it comes from pooled trial data rather than any single study. A 2023 systematic review and meta-analysis of randomized controlled trials covering 546 participants found nattokinase supplementation reduced systolic blood pressure by a mean difference of −3.45 mmHg and diastolic blood pressure by −2.32 mmHg compared to placebo.

Those numbers sound small next to what a prescription antihypertensive delivers, but a consistent modest systolic drop across a population can have meaningful effects. Population-level blood pressure research has long shown that reductions in this range correlate with lower cardiovascular event rates over time, particularly for people starting in the prehypertensive or stage 1 hypertensive range rather than those with severe, uncontrolled hypertension.

Here is how the pooled results break down against what you would see in a general antihypertensive lifestyle intervention:

Measure Nattokinase (pooled RCT data) Clinical context
Systolic blood pressure change −3.45 mmHg vs. placebo Comparable to the effect of modest sodium reduction
Diastolic blood pressure change −2.32 mmHg vs. placebo Similar magnitude to increased physical activity alone
Population studied Prehypertensive to stage 1 hypertensive adults Not tested primarily in severe or resistant hypertension
Evidence source 546 participants across pooled RCTs Smaller than typical pharmaceutical trial cohorts

The trials feeding that meta-analysis varied in duration, dosing, and the specific population enrolled, which is exactly why the confidence intervals around those pooled numbers imply that reviewers called for more standardized research. Dose also appears to matter more than early marketing suggested: an insight from the same meta-analysis notes that antihypertensive benefits tend to show up more reliably at higher total daily fibrinolytic unit (FU) doses, not in the lowest-dose short trials. Heterogeneity across studies, meaning differences in how each trial was designed and measured, remains one of the biggest limitations reviewers flag when interpreting these pooled results.

Can Nattokinase Dissolve Blood Clots? Antithrombotic Evidence Explained

Nattokinase’s reputation as a clot-dissolving supplement started with animal research, and the numbers from those early studies are genuinely striking. In carotid thrombosis models, nattokinase administration restored up to 62% of arterial blood flow that had been blocked by an induced clot. Separate animal work found rapid dissolution of venous thrombi within hours when doses were high enough, using formulations delivering roughly 2,000 FU per capsule in canine models.

Human evidence is less dramatic but still meaningful, built mostly around biomarkers rather than hard clinical outcomes like stroke or heart attack prevention:

  • Fibrin degradation products (FDPs) show transient increases after nattokinase ingestion, indicating the enzyme is actively breaking down clotting material in circulation.
  • Factor VII and Factor VIII, two clotting proteins, decreased in a small human trial where participants took two 2,000 FU capsules daily for two months, according to the oral antithrombotic review.
  • Fibrinogen levels, a marker tied to clot formation risk, dropped modestly in that same trial without notable adverse events reported.
  • D-dimer, a widely used clinical marker of clot activity, has been examined in smaller studies exploring deep vein thrombosis (DVT) prevention, including interest in post-flight risk reduction for long-haul travelers.

Preclinical potency does not automatically translate into equivalent human clinical benefit, and no controlled human trial has replicated that exact endpoint.

The practical difference between nattokinase and a prescription thrombolytic like tissue plasminogen activator (tPA) is scale and speed. Prescription thrombolytics are designed to rapidly dissolve life-threatening clots under hospital monitoring, with tightly controlled dosing and bleeding-risk management. Nattokinase works through a slower, milder version of a similar pathway, taken orally over weeks or months, without the same monitoring infrastructure. That gap is exactly why safety oversight matters more, not less, when someone is combining it with other medications.

Beyond Blood Pressure: Lipids, Inflammation, and Brain Health Claims

Nattokinase marketing often reaches well past blood pressure and clotting into cholesterol management, inflammation control, and even cognitive protection. Some of that reach is backed by real preclinical signal. Much of it is not backed by human trials at all, and the two categories deserve to be kept separate.

On lipids, the picture is genuinely mixed. Some trials using standard 2,000 FU daily doses found no meaningful improvement in cholesterol or triglyceride markers. A review of nattokinase’s mechanisms in age-related disease notes that plaque and carotid intima media thickness improvements have shown up mainly in studies using much higher doses, in the range of 10,800 FU per day, suggesting lipid and arterial-stiffness benefits may require a dosing threshold that most consumer supplements do not reach.

On inflammation and neuroprotection, the evidence sits almost entirely in test tubes and animal models:

  • Anti-inflammatory signaling. Preclinical studies report nattokinase suppressing LPS-induced TLR4 signaling and lowering reactive oxygen species production in animal models of chronic inflammation.
  • Amyloid-related lab work. Bench research has explored whether nattokinase can degrade amyloid proteins associated with neurodegenerative disease, but this work has not moved into human clinical trials.
  • Cognitive function claims. No controlled human trial currently supports nattokinase for memory, focus, or dementia prevention, despite the enzyme’s popularity in some nootropic-adjacent marketing.

Treat all three of these as promising research directions, not reasons to choose nattokinase over established therapies. If you’re managing high cholesterol or a neurodegenerative risk factor, this supplement should sit alongside your regular care plan at most, never replace it.

Nattokinase Safety: Bleeding Risk, Drug Interactions, and Who Should Avoid It

The same fibrinolytic action that makes nattokinase interesting for cardiovascular support is exactly what makes it risky for certain people. Because it thins the blood’s clotting response, combining it with anticoagulants (like warfarin) or antiplatelet drugs (like aspirin or clopidogrel) can compound bleeding risk in ways that are not well studied in humans. Memorial Sloan Kettering Cancer Center’s clinical guidance states plainly that nattokinase should not replace prescribed anticoagulant therapy and that anyone on blood thinners needs clinician oversight before adding it.

Beyond bleeding concerns, most reported side effects are mild. Gastrointestinal symptoms, including bloating, mild diarrhea, or stomach discomfort, show up occasionally in trial reports. Rare adverse events have been noted in case reports, though systematic data on their frequency is limited given how small most trials remain.

Two situations deserve specific caution:

  • Before surgery. Because nattokinase affects clotting, most clinical guidance suggests stopping it at least one to two weeks before any planned surgical procedure, similar to standard advice for other blood-thinning supplements.
  • During pregnancy. Safety data in pregnant or breastfeeding people is essentially absent, which means the responsible default is avoidance unless a physician says otherwise.

Before starting nattokinase, work through these steps:

  1. Talk to your clinician first, especially if you take any prescription medication.
  2. List every medication and supplement you currently take, including over-the-counter aspirin or fish oil, both of which also affect clotting.
  3. Ask about baseline labs if you’re on anticoagulants. Clinical guidance recommends checking baseline INR and following up with INR or PT monitoring where applicable.
  4. Watch for warning signs like unexplained bruising, blood in urine, or bleeding gums during use.
  5. Schedule a surgical pause into your calendar if a procedure is upcoming.

Pro Tip: If you’re already tracking blood pressure or cholesterol at home, log your numbers for two weeks before starting nattokinase. That baseline makes it much easier to tell whether the supplement is doing anything, rather than guessing based on how you feel.

What Does Nattokinase Dosage Actually Look Like on a Label?

Nattokinase dosing is measured in fibrinolytic units, abbreviated FU, which quantify enzyme activity rather than raw milligram weight. This matters because two capsules with identical milligram amounts can have very different FU potency depending on how the enzyme was processed and standardized.

Most consumer supplements land around 2,000 FU per day, which mirrors the dose used in several of the smaller human biomarker trials. Higher-dose research protocols have tested 6,000 to 10,800 FU per day, and those are the doses more consistently associated with the plaque and arterial-stiffness improvements discussed earlier. The gap between a standard retail dose and a research-grade dose is worth understanding before you assume a bottle will replicate a study’s results.

Key figure to remember: active nattokinase remains detectable in plasma for approximately 8 to 12 hours after ingestion, which is why some higher-dose protocols split servings across morning and evening rather than taking everything at once.

Eating natto itself delivers nattokinase in its natural food form, but the enzyme content varies by batch and preparation, and the fermented flavor is not for everyone. Supplements offer more dosing consistency, provided the label actually states FU content.

When comparing products, look for a few concrete things:

  • FU units listed explicitly on the supplement facts panel, not just a generic “proprietary enzyme blend.”
  • Third-party testing disclosed by the manufacturer, which verifies potency claims independently.
  • A transparent ingredient list with no unnamed fillers standing in for active enzyme content.
  • Clear per-capsule dosage, so you can calculate your actual daily FU total against what trials have tested.

Where the Nattokinase Research Still Falls Short

The honest limitation across nearly every nattokinase study is scale. The 2023 meta-analysis that anchors most of the blood pressure evidence pooled just 546 participants, a fraction of what a pharmaceutical-grade cardiovascular trial would enroll. Reviewers behind that same analysis explicitly call for larger, longer randomized trials before treating nattokinase as a reliable clinical intervention rather than a promising supplement.

Three gaps stand out. Trials need standardized FU dosing so results can actually be compared across studies. They need clinically meaningful endpoints, meaning stroke rates, major cardiovascular events, or confirmed DVT recurrence, rather than biomarker proxies alone. And they need longer follow-up periods and more diverse populations, including people already on cardiovascular medications, to see how nattokinase behaves in real-world combination therapy.

Nattokinase sits in an unusual research position: it has more mechanistic and animal-model support than most supplements ever get, yet the human clinical trial base remains small enough that no major medical body treats it as a substitute for standard cardiovascular care.

Until larger trials close that gap, the honest framing is “promising and mechanistically plausible,” not “proven.”

Does Nattokinase Cause Side Effects Beyond Bleeding?

Bleeding risk gets most of the attention, but it is not the only consideration. Gastrointestinal upset, including mild bloating or loose stools, appears in a subset of trial participants and is usually described as manageable rather than severe. Because nattokinase comes from fermented soy, anyone with a soy allergy should avoid it entirely, even though the fermentation process alters the protein structure somewhat from raw soy.

There is also a theoretical concern around blood pressure that runs the opposite direction from the supplement’s main benefit: people already on antihypertensive medication could see an additive drop in blood pressure that pushes them toward symptomatic hypotension, particularly dizziness or lightheadedness when standing. This has not been documented extensively in trials, but it follows logically from the mechanism, and it is worth watching for during the first few weeks of use.

Liver considerations deserve a mention too. While nattokinase itself has not been strongly linked to liver toxicity in the available research, anyone managing liver disease should be cautious layering new supplements onto an already compromised metabolic system. If that describes your situation, a conversation with your doctor about safer supplement choices for your specific liver condition is worth having before adding anything new to your routine.

Nattokinase is not commonly associated with the kind of severe allergic reactions or organ-specific toxicity that would put it in a high-risk category. But “generally mild” is not the same as “risk-free,” especially in combination with other medications.

Nattokinase Benefits: A Reasonable Option for Some, Not a Cure-All

Nattokinase makes the most sense for someone with mildly elevated blood pressure who has already nailed the fundamentals, diet, exercise, sleep, and wants a supplement with real mechanistic backing rather than marketing hype. It makes far less sense as a substitute for prescribed cardiovascular treatment, and it is a clear no for anyone on anticoagulants without direct physician involvement.

Red flags that should stop you before starting: any anticoagulant or antiplatelet prescription, an upcoming surgery, pregnancy, or a soy allergy. If none of those apply, the reasonable path is starting at standard doses, tracking your numbers, and treating this as a complement to established care rather than a replacement for it.

Bring the specific FU dose to your provider, not just the supplement name. That detail is what lets them actually weigh it against your other medications.

— Armando

How to Choose a Quality Nattokinase Supplement

Once you’ve talked to your provider and decided nattokinase fits your situation, the next challenge is picking a product that actually matches what the research tested. A lot of supplements skip FU labeling entirely, which makes it impossible to know if you’re getting anything close to a studied dose.

Nexoclub

Run any nattokinase product through this checklist before buying: does the label state FU units per capsule, not just milligrams? Has the manufacturer disclosed third-party testing for potency and purity? Is the ingredient list transparent, with no vague “proprietary blend” hiding the actual enzyme source? Nexoclub’s supplements and nutrition collection is organized around exactly this kind of label transparency, making it easier to compare fibrinolytic and cardiovascular-support formulas side by side rather than hunting across scattered retailers. If you’re also managing blood pressure through diet and lifestyle, a circulation-support formula can complement that approach. For broader questions about medication interactions and supplement safety, Vitalonga’s guidance on supplement side effects is a useful outside resource worth reading alongside your own research. Browse the supplements collection, check FU labeling against what you’ve read here, and reach out through Nexoclub’s site if you have questions before checkout.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

Sources

Back to blog